Medical Doctor Program year 2024 Reported 2019–2024 Source: CMS Open Payments, 2026 publication

Allen McCulloch

Urology Farmington, NM Medical Doctor

NPI 1881778215 CMS profile 673327

2300 E 30Th, Bldg B Suite 106, Farmington, NM 87401

Open in the dashboard

General payments

$1,522

17 records reported · program years 2019–2024

Research payments

$0

Paid to them · None reported · program years 2019–2024

Ownership & investment interest

$0

None reported

Through program year 2024, Allen McCulloch of Farmington, NM is reported in the CMS Open Payments database as having received $1,522 across 17 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 39th percentile of Urology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2024 General $97 2
2023 General $38 2
2022 General $13 1
2020 General $84 3
2019 General $1,290 9

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Allen McCulloch
  • Urology median
  • Middle half of Urology
  • National median

In program year 2025, general payments to Allen McCulloch were reported at $0. Among 9,461 Urology profiles paid that year, the median was $629 and the middle half received between $190 and $1,620.

Show as a table
Year Allen McCulloch Urology median Middle half National median
2019 $1,290 $480 $147–$1,201 $163
2020 $84 $246 $87–$645 $114
2021 $0 $358 $111–$1,000 $132
2022 $13 $476 $143–$1,263 $149
2023 $38 $560 $168–$1,461 $160
2024 $97 $563 $170–$1,464 $164
2025 $0 $629 $190–$1,620 $169

Breakdown

Who paid General payments · program years 2019–2024
  1. NeoTract Inc. $1,322 10 payments
  2. Teleflex LLC $90 2 payments
  3. Stryker Corporation $40 1 payment
  4. PROCEPT BioRobotics Corporation $28 1 payment
  5. ConvaTec Inc. $18 1 payment
  6. Bayer HealthCare Pharmaceuticals Inc. $13 1 payment
  7. Astellas Pharma US Inc $12 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2024
  1. Travel and Lodging $877 1 payment
  2. Food and Beverage $645 16 payments
Products named General payments · program years 2019–2024
  1. UROLIFT $1,342 11 payments
  2. CROSSFIRE 2 INTEGRATED RESECTION & ENERGY SYSTEM $40 1 payment
  3. SERFAS ENERGY PROBES $40 1 payment
  4. AQUABEAM SYSTEM $28 1 payment
  5. GENTLECATH $18 1 payment
  6. Nubeqa $13 1 payment
  7. VESICARE $12 1 payment
  8. MYRBETRIQ $12 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 17 drugs

Part D claims

1,828

Median for Urology: 1,053

Drug cost

$187,653

Median for Urology: $101,464

Branded share of claims

11.9%

Median for Urology: 27.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Nubeqa Darolutamide Brand 12 $155,190
Finasteride Generic 611 $9,015
Doxazosin Mesylate Generic 445 $6,446
Tamsulosin Hcl Generic 255 $4,289
Methenamine Hippurate Generic 40 $2,476
Oxybutynin Chloride Er Oxybutynin Chloride Brand 156 $2,296
Estradiol Generic 28 $1,589
Dutasteride Generic 38 $1,415
Bicalutamide Generic 57 $1,049
Testosterone Generic 12 $905

The 10 drugs with the highest cost, of 17 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 10,221 Part D prescribers listed as Urology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 56 billing codes

Paid by Medicare

$174,052

Of which drugs: $29,183

Medicare patients

698

Average age 76

Services billed

11,115

55 women, 643 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 67%
Arthritis 40%
Diabetes 31%
Ischemic heart disease 27%
Cancer 21%
Atrial fibrillation 18%
Chronic kidney disease 18%
COPD 13%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Leuprolide acetate (for depot suspension), 7.5 mg J9217 Office 31 171 $23,544

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

17 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Urology in New Mexico

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2024

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record